Lord, Abbett & Co
FPRX

Lord, Abbett & Co’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Lord, Abbett & Co’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-102,289
Closed -$4.18M – 933
2017
Q3 		$4.18M Buy
102,289
+44,260
+76% +$1.39M 0.01% 790
2017
Q2 		$1.75M Sell
58,029
-979
-2% -$30.6K 0.01% 861
2017
Q1 		$2.13M Sell
59,008
-55,389
-48% -$2.44M 0.01% 831
2016
Q4 		$5.73M Buy
114,397
+1,335
+1% +$70.1K 0.02% 714
2016
Q3 		$5.93M Sell
113,062
-83,288
-42% -$3.98M 0.02% 698
2016
Q2 		$8.12M Buy
196,350
+34,995
+22% +$1.52M 0.03% 620
2016
Q1 		$6.55M Buy
161,355
+8,929
+6% +$307K 0.02% 644
2015
Q4 		$6.33M Buy
152,426
+1,653
+1% +$55.4K 0.02% 686
2015
Q3 		$2.32M Sell
150,773
-125,093
-45% -$2.69M 0.01% 832
2015
Q2 		$6.85M Buy
+275,866
New +$6.15M 0.02% 710

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Lord, Abbett & Co's FPRX Position: Q4 2017 in Review

Lord, Abbett & Co sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2017, closing a stake of 102,289 shares — an estimated $4.18M sold.

Lord, Abbett & Co first reported a position in FPRX in Q2 2015 and held it in 10 quarters. The position peaked at $8.12M in Q2 2016. 137 funds tracked by Wall St. Rank hold FPRX as of Q4 2017.

  • Lord, Abbett & Co reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Lord, Abbett & Co sold 102,289 Five Prime Therapeutics, Inc. shares in Q4 2017, an estimated $4.18M.
  • Lord, Abbett & Co first reported a position in Five Prime Therapeutics, Inc. in Q2 2015 and held it in 10 quarters.
  • Lord, Abbett & Co's Five Prime Therapeutics, Inc. position peaked at $8.12M in Q2 2016.
  • 137 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2017.

Based on Lord, Abbett & Co's 13F filing for Q4 2017, filed 14 Feb 2018.